药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Trilostane
Cilostazol
The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Indacaterol.
Trilostane
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Tetrahydropalmatine.
Trilostane
Lacidipine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Lacidipine.
Trilostane
Efonidipine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Efonidipine.
Trilostane
Alimemazine
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Indacaterol.
Trilostane
Inotersen
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Inotersen.
Trilostane
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pipemidic acid.
Trilostane
Rufloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Rufloxacin.
Trilostane
Piromidic acid
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Piromidic acid.
Trilostane
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Acetyldigoxin.
Trilostane
Lorajmine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Lorajmine.
Trilostane
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Oxolinic acid.
Trilostane
Prajmaline
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Prajmaline.
Trilostane
Cibenzoline
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Cibenzoline.
Trilostane
Cicletanine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Cicletanine.
Trilostane
Pilsicainide
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pilsicainide.
Trilostane
Givinostat
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Givinostat.
Trilostane
Temefos
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Temefos.
Trilostane
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Prulifloxacin.
Trilostane
CUDC-907
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with CUDC-907.